Investigational drug · Phase 2
CS-1103
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Methamphetamine Intoxication, Methamphetamine Disorders, Methamphetamine Abuse.
Phase 2Last checked: Nov 19, 2026Latest source record: Nov 10, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
2
0 still active
All registered trials
3
Any phase or sponsor naming "CS-1103"
First trial start
2026
Feb 5, 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "CS-1103", any sponsor or status.
Conditions studied
As listed on its trial records.
- Methamphetamine Intoxication
- Methamphetamine Disorders
- Methamphetamine Abuse
- Fentanyl Overdose
- Fentanyl Poisoning
Largest trials
Live from ClinicalTrials.gov: studies naming "CS-1103" as an intervention, largest first.
Clear Scientific, Inc.Industry
NCT06721494 · 34 participants · Start Feb 5, 2026 · Primary completion Oct 24, 2026
Drug: Methamphetamine; Sterile Saline and 1 more · For: Methamphetamine Intoxication; Methamphetamine Disorders; Methamphetamine Abuse
Sites: Glendale, California
Clear Scientific, Inc.Industry
NCT06316973 · 32 participants · Start Feb 7, 2024 · Primary completion May 30, 2024
Drug: CS-1103; Sterile Saline · For: Substance Use Disorders; Methamphetamine Abuse; Methamphetamine Intoxication
Sites: Overland Park, Kansas
Clear Scientific, Inc.Industry
NCT07459166 · 16 participants · Start May 28, 2026 · Primary completion Jul 15, 2026
Drug: Naloxone Hydrochloride; Fentanyl and 2 more · For: Fentanyl Overdose; Fentanyl Poisoning
Sites: Glendale, California
Newest research
PubMed records naming it or its code names, newest first.
- A novel drug sequestrant-based therapeutic candidate reverses methamphetamine-induced hyperthermia and hypermetabolism and abates multiorgan toxicity in rats.
Cotten JF, Marota JJ, Adam E · J Pharmacol Exp Ther 2026
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.